XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Details
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Details

5. Balance Sheet Details

Inventory consisted of the following (in thousands):

 

 

 

June 30,
2023

 

 

December 31,
2022

 

Finished goods

 

$

2,004

 

 

$

1,926

 

Work in process

 

 

5,310

 

 

 

4,427

 

Raw material

 

 

6,809

 

 

 

5,207

 

 

 

$

14,123

 

 

$

11,560

 

Reported as:

 

 

 

 

 

 

    Inventory

 

$

9,199

 

 

$

6,636

 

    Long-term inventory

 

 

4,924

 

 

 

4,924

 

    Total

 

$

14,123

 

 

$

11,560

 

Amount reported as long-term inventory consisted of raw materials for NUPLAZID as of June 30, 2023 and December 31, 2022. The Company has raw materials beyond a one year production plan that help limit the exposures from potential supply interruption. Those raw materials beyond the one year production plan were classified as long-term inventory.

Accrued liabilities consisted of the following (in thousands):

 

 

 

June 30,
2023

 

 

December 31,
2022

 

Accrued sales allowances

 

$

47,423

 

 

$

26,046

 

Accrued research and development services

 

 

31,697

 

 

 

35,048

 

Accrued contingent payments

 

 

29,583

 

 

 

—

 

Accrued compensation and benefits

 

 

25,413

 

 

 

28,023

 

Accrued consulting and professional fees

 

 

12,242

 

 

 

11,377

 

Current portion of lease liabilities

 

 

9,058

 

 

 

9,305

 

Current portion of accrued branded prescription drug fees

 

 

7,828

 

 

 

1,060

 

Other

 

 

5,887

 

 

 

2,025

 

 

 

$

169,131

 

 

$

112,884